Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial

INTRODUCTION: iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (iGlar, 100 units/ml) and the glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of patients with type 2 diabetes. This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Blonde, Lawrence, Bailey, Timothy S., Chao, Jason, Dex, Terry A., Frias, Juan Pablo, Meneghini, Luigi F., Roberts, Michelle, Aroda, Vanita R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822975/
https://www.ncbi.nlm.nih.gov/pubmed/31359368
http://dx.doi.org/10.1007/s12325-019-01033-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822975/
https://www.ncbi.nlm.nih.gov/pubmed/31359368
http://dx.doi.org/10.1007/s12325-019-01033-1

Ejemplares similares